000 01241 a2200361 4500
005 20250517172702.0
264 0 _c20180510
008 201805s 0 0 eng d
022 _a1750-7448
024 7 _a10.2217/imt-2017-0039
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aZhang, Minghui
245 0 0 _aApplication of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
_h[electronic resource]
260 _bImmunotherapy
_c09 2017
300 _a851-861 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aCancer Vaccines
_ximmunology
650 0 4 _aFemale
650 0 4 _aGenetic Therapy
650 0 4 _aHumans
650 0 4 _aImmunotherapy, Adoptive
_xmethods
650 0 4 _aOvarian Neoplasms
_ximmunology
650 0 4 _aReceptors, Antigen, T-Cell
_xgenetics
650 0 4 _aRecombinant Fusion Proteins
_xgenetics
650 0 4 _aSignal Transduction
650 0 4 _aT-Lymphocytes
_xphysiology
650 0 4 _aTranslational Research, Biomedical
700 1 _aZhang, Dr Bin
700 1 _aShi, Huirong
773 0 _tImmunotherapy
_gvol. 9
_gno. 10
_gp. 851-861
856 4 0 _uhttps://doi.org/10.2217/imt-2017-0039
_zAvailable from publisher's website
999 _c27533278
_d27533278